Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma

Scott E. Jordan, Ida Micaily, Enrique Hernandez, Stuart Ferriss, Curtis T. Miyamoto, Shidong Li, Bizhan Micaily

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose The purpose of this case series is to describe the treatment and outcomes of a cohort of patients with inoperable early-stage endometrioid endometrial cancer with 3D image-guided high-dose-rate (HDR) intracavitary brachytherapy. Materials and Methods A review was performed of patients with early-stage endometrial cancer who underwent primary radiation treatment between 2010 and 2016. Staging and treatment planning were performed CT, pelvic ultrasound, and pelvic MRI. Gross tumor volume (GTV) was defined as the MRI or ultrasound demonstrated endometrial stripe width, with the entire uterine corpus, cervix, and proximal vagina representing the clinical target volume (CTV). Dosimetry calculations were performed in each fraction of HDR brachytherapy. RESULTS Eight patients received external beam radiation therapy followed by intracavitary HDR brachytherapy. Seven patients underwent intracavitary HDR brachytherapy alone. In all patients, mean cumulative dose to 90% (D90) of GTV was 95.99 Gy in equivalent dose in 2 Gy fractions (EQD2, α/β = 10). Mean cumulative D90 EQD2 to CTV was 51.64 Gy. Average follow-up was 29 months. Four patients died from concurrent disease(s) at an average of 2.83 years after completion of treatment. Except for 1 (6.6%) patient who recurred at 9 months following completion of treatment, all patients remained disease-free for the remainder of follow-up. Conclusions In patients who are poor surgical candidates and have early-stage endometrioid type endometrial carcinoma, image-guided HDR intracavitary brachytherapy carries minimal side effects and a high response rate.

Original languageEnglish (US)
Pages (from-to)1144-1151
Number of pages8
JournalBrachytherapy
Volume16
Issue number6
DOIs
StatePublished - Nov 1 2017

Fingerprint

Endometrioid Carcinoma
Brachytherapy
Endometrial Neoplasms
Therapeutics
Tumor Burden
Vagina
Cervix Uteri
Radiotherapy
Radiation

Keywords

  • Computer assisted dosimetry calculations
  • Endometrial cancer
  • Endometrioid adenocarcinoma
  • Intracavitary brachytherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. / Jordan, Scott E.; Micaily, Ida; Hernandez, Enrique; Ferriss, Stuart; Miyamoto, Curtis T.; Li, Shidong; Micaily, Bizhan.

In: Brachytherapy, Vol. 16, No. 6, 01.11.2017, p. 1144-1151.

Research output: Contribution to journalArticle

Jordan, Scott E. ; Micaily, Ida ; Hernandez, Enrique ; Ferriss, Stuart ; Miyamoto, Curtis T. ; Li, Shidong ; Micaily, Bizhan. / Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. In: Brachytherapy. 2017 ; Vol. 16, No. 6. pp. 1144-1151.
@article{a387e1c2361743ff971bb96282a88ed7,
title = "Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma",
abstract = "Purpose The purpose of this case series is to describe the treatment and outcomes of a cohort of patients with inoperable early-stage endometrioid endometrial cancer with 3D image-guided high-dose-rate (HDR) intracavitary brachytherapy. Materials and Methods A review was performed of patients with early-stage endometrial cancer who underwent primary radiation treatment between 2010 and 2016. Staging and treatment planning were performed CT, pelvic ultrasound, and pelvic MRI. Gross tumor volume (GTV) was defined as the MRI or ultrasound demonstrated endometrial stripe width, with the entire uterine corpus, cervix, and proximal vagina representing the clinical target volume (CTV). Dosimetry calculations were performed in each fraction of HDR brachytherapy. RESULTS Eight patients received external beam radiation therapy followed by intracavitary HDR brachytherapy. Seven patients underwent intracavitary HDR brachytherapy alone. In all patients, mean cumulative dose to 90{\%} (D90) of GTV was 95.99 Gy in equivalent dose in 2 Gy fractions (EQD2, α/β = 10). Mean cumulative D90 EQD2 to CTV was 51.64 Gy. Average follow-up was 29 months. Four patients died from concurrent disease(s) at an average of 2.83 years after completion of treatment. Except for 1 (6.6{\%}) patient who recurred at 9 months following completion of treatment, all patients remained disease-free for the remainder of follow-up. Conclusions In patients who are poor surgical candidates and have early-stage endometrioid type endometrial carcinoma, image-guided HDR intracavitary brachytherapy carries minimal side effects and a high response rate.",
keywords = "Computer assisted dosimetry calculations, Endometrial cancer, Endometrioid adenocarcinoma, Intracavitary brachytherapy",
author = "Jordan, {Scott E.} and Ida Micaily and Enrique Hernandez and Stuart Ferriss and Miyamoto, {Curtis T.} and Shidong Li and Bizhan Micaily",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.brachy.2017.08.006",
language = "English (US)",
volume = "16",
pages = "1144--1151",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma

AU - Jordan, Scott E.

AU - Micaily, Ida

AU - Hernandez, Enrique

AU - Ferriss, Stuart

AU - Miyamoto, Curtis T.

AU - Li, Shidong

AU - Micaily, Bizhan

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose The purpose of this case series is to describe the treatment and outcomes of a cohort of patients with inoperable early-stage endometrioid endometrial cancer with 3D image-guided high-dose-rate (HDR) intracavitary brachytherapy. Materials and Methods A review was performed of patients with early-stage endometrial cancer who underwent primary radiation treatment between 2010 and 2016. Staging and treatment planning were performed CT, pelvic ultrasound, and pelvic MRI. Gross tumor volume (GTV) was defined as the MRI or ultrasound demonstrated endometrial stripe width, with the entire uterine corpus, cervix, and proximal vagina representing the clinical target volume (CTV). Dosimetry calculations were performed in each fraction of HDR brachytherapy. RESULTS Eight patients received external beam radiation therapy followed by intracavitary HDR brachytherapy. Seven patients underwent intracavitary HDR brachytherapy alone. In all patients, mean cumulative dose to 90% (D90) of GTV was 95.99 Gy in equivalent dose in 2 Gy fractions (EQD2, α/β = 10). Mean cumulative D90 EQD2 to CTV was 51.64 Gy. Average follow-up was 29 months. Four patients died from concurrent disease(s) at an average of 2.83 years after completion of treatment. Except for 1 (6.6%) patient who recurred at 9 months following completion of treatment, all patients remained disease-free for the remainder of follow-up. Conclusions In patients who are poor surgical candidates and have early-stage endometrioid type endometrial carcinoma, image-guided HDR intracavitary brachytherapy carries minimal side effects and a high response rate.

AB - Purpose The purpose of this case series is to describe the treatment and outcomes of a cohort of patients with inoperable early-stage endometrioid endometrial cancer with 3D image-guided high-dose-rate (HDR) intracavitary brachytherapy. Materials and Methods A review was performed of patients with early-stage endometrial cancer who underwent primary radiation treatment between 2010 and 2016. Staging and treatment planning were performed CT, pelvic ultrasound, and pelvic MRI. Gross tumor volume (GTV) was defined as the MRI or ultrasound demonstrated endometrial stripe width, with the entire uterine corpus, cervix, and proximal vagina representing the clinical target volume (CTV). Dosimetry calculations were performed in each fraction of HDR brachytherapy. RESULTS Eight patients received external beam radiation therapy followed by intracavitary HDR brachytherapy. Seven patients underwent intracavitary HDR brachytherapy alone. In all patients, mean cumulative dose to 90% (D90) of GTV was 95.99 Gy in equivalent dose in 2 Gy fractions (EQD2, α/β = 10). Mean cumulative D90 EQD2 to CTV was 51.64 Gy. Average follow-up was 29 months. Four patients died from concurrent disease(s) at an average of 2.83 years after completion of treatment. Except for 1 (6.6%) patient who recurred at 9 months following completion of treatment, all patients remained disease-free for the remainder of follow-up. Conclusions In patients who are poor surgical candidates and have early-stage endometrioid type endometrial carcinoma, image-guided HDR intracavitary brachytherapy carries minimal side effects and a high response rate.

KW - Computer assisted dosimetry calculations

KW - Endometrial cancer

KW - Endometrioid adenocarcinoma

KW - Intracavitary brachytherapy

UR - http://www.scopus.com/inward/record.url?scp=85029674657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029674657&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2017.08.006

DO - 10.1016/j.brachy.2017.08.006

M3 - Article

VL - 16

SP - 1144

EP - 1151

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 6

ER -